Lichen planus‐like lesion preceding bullous pemphigoid development after programmed cell death protein‐1 inhibitor treatment

2020 ◽  
Author(s):  
Arisa Sugawara ◽  
Hiroshi Koga ◽  
Toshifumi Abe ◽  
Norito Ishii ◽  
Takekuni Nakama
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Bullous Pemphigoid ◽  
Lichen Planus ◽  
Cell Death Protein ◽  
Inhibitor Treatment

scholarly journals Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis

2018 ◽  
Vol 34 (1) ◽  
pp. 108-117 ◽  
Author(s):  
Sandhya Manohar ◽  
Panagiotis Kompotiatis ◽  
Charat Thongprayoon ◽  
Wisit Cheungpasitporn ◽  
Joerg Herrmann ◽  
...  
Keyword(s):  
Acute Kidney Injury ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Meta Analysis ◽  
Kidney Injury ◽  
Cell Death Protein ◽  
Inhibitor Treatment

scholarly journals Pemphigus Herpetiformis-Type Drug Reaction Caused by Programmed Cell Death Protein-1 Inhibitor Treatment

2021 ◽  
Vol Volume 14 ◽  
pp. 1125-1129
Author(s):  
Yunfang Zhang ◽  
Ming Zhang ◽  
Jianping Xie ◽  
Weiwei Wu ◽  
Jiejie Lu
Keyword(s):  
Cell Death ◽  
Drug Reaction ◽  
Programmed Cell Death ◽  
Cell Death Protein ◽  
Inhibitor Treatment

scholarly journals Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Ece Esin
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Checkpoint Inhibitors ◽  
Innate Immune ◽  
Small Subset ◽  
New Class ◽  
Combination Strategies ◽  
Combination Methods ◽  
Immune Editing ◽  
Cell Death Protein

In the last decade, we have gained a deeper understanding of innate immune system. The mechanism of the continuous guarding of progressive mutations happening in a single cell was discovered and the production and the recognition of tumor associated antigens by the T-cells and elimination of numerous tumors by immune-editing were further understood. The new discoveries on immune mechanisms and its relation with carcinogenesis have led to development of a new class of drugs called immunotherapeutics. T lymphocyte-associated antigen 4, programmed cell death protein 1, and programmed cell death protein ligand 1 are the classes drugs based on immunologic manipulation and are collectively known as the “checkpoint inhibitors.” Checkpoint inhibitors have shown remarkable antitumor efficacy in a broad spectrum of malignancies; however, the strongest and most durable immune responses do not last long and the more durable responses only occur in a small subset of patients. One of the solutions which have been put forth to overcome these challenges is combination strategies. Among the dual use of methods, a backbone with either PD-1 or PD-L1 antagonist drugs alongside with certain cytotoxic chemotherapies, radiation, targeted drugs, and novel checkpoint stimulators is the most promising approach and will be on stage in forthcoming years.

Sign in / Sign up

Export Citation Format

Share Document